Individual measures of disease activity at Week 12.
| Probiotic, n = 32, | Placebo, n = 31, | Probiotic Effect (95% CI) | |||
|---|---|---|---|---|---|
| Baseline, mean (SD) | Week 12, mean (SD) | Baseline, mean (SD) | Week 12, mean (SD) | ||
| BASFI | 3.5 (2.0) | 2.9 (1.9) | 3.6 (1.9) | 3.1 (2.2) | −0.1 (−0.7–0.6) |
| BASDAI | 4.2 (2.2) | 3.2 (2.1) | 4.5 (2.0) | 3.9 (2.2) | −0.6 (−1.6–0.3) |
| Patient global VAS | 3.4 (2.2) | 2.7 (2.0) | 4.0 (2.4) | 3.3 (2.4) | −0.4 (−1.4–0.7) |
| Pain VAS | 2.9 (2.3) | 2.7 (2.5) | 3.0 (2.6) | 2.6 (2.2) | 0.2 (−0.8–1.1) |
| Tender joint count | 2.0 (2.1) | 3.1 (3.9) | 2.6 (2.6) | 5.4 (8.8) | −1.6 (−4.6–1.5) |
| Swollen joint count | 0.4 (0.9) | 0.25 (0.9) | 0.5 (1.1) | 0.2 (0.5) | 0.1 (−0.2–0.4) |
| MASES | 3.5 (2.7) | 2.3 (3.0) | 3.8 (2.9) | 2.9 (3.2) | −0.4 (−1.5–0.6) |
| BASMI | 2.7 (2.6) | 2.3 (2.3) | 2.7 (3.0) | 2.4 (3.0) | −0.01 (−0.6–0.6) |
| CRP | 6.8 (6.7) | 6.7 (6.3) | 10.0 (11.3) | 11.3 (11.2) | −3.5 (−7.8–0.8) |
| ASQoL | 6.9 (4.5) | 4.9 (4.8) | 6.4 (4.3) | 5 (4.7) | −0.5 (−2.0–1.1) |
| MAF | 24.3 (11.7) | 21.9 (10.2) | 25.8 (11.4) | 23.9 (11.1) | −1.2 (−5.9–3.4) |
| DISQ | 8.2 (4.7) | 6.6 (5.1) | 10.1 (6.7) | 8.8 (8.0) | −1.2 (−4.3–1.9) |
BASFI: Bath AS Functional Index; BASDAI: Bath AS Disease Activity Index; VAS: visual analog scale; MASES: Maastrict AS Enthesitis Score; BASMI: Bath AS Metrology Index; CRP: C-reactive protein; ASQoL: AS Quality of Life questionnaire; MAF: Multidimensional Assessment of Fatigue; DISQ: Dudley Inflammatory Bowel Symptom Questionnaire.